Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 45.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 664,205 shares of the biopharmaceutical company’s stock after buying an additional 206,404 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Bristol-Myers Squibb were worth $37,567,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Morse Asset Management Inc boosted its position in Bristol-Myers Squibb by 25.0% during the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 2,000 shares during the period. Tudor Financial Inc. bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth $250,000. Pine Valley Investments Ltd Liability Co raised its stake in shares of Bristol-Myers Squibb by 1.3% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company’s stock worth $2,323,000 after buying an additional 575 shares in the last quarter. World Investment Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 18.7% in the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company’s stock worth $2,282,000 after buying an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth $1,724,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In related news, EVP Samit Hirawat acquired 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Up 1.1 %

Shares of NYSE BMY opened at $48.45 on Tuesday. The business has a 50-day moving average of $56.24 and a 200-day moving average of $56.50. The firm has a market capitalization of $98.58 billion, a price-to-earnings ratio of -10.96, a PEG ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the previous year, the firm posted ($4.40) EPS. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.12%. Bristol-Myers Squibb’s payout ratio is 92.88%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BMY. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Friday, February 7th. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target on the stock. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Finally, Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.